Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dendritic cell-based immunotherapy in multiple myeloma.

Qing Yi1

  • 1Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot #776, Little Rock, AR 72205, USA. yiqing@uams.edu

Leukemia & Lymphoma
|February 13, 2004
PubMed
Summary

Dendritic cell (DC) immunotherapy offers a promising approach to combat multiple myeloma (MM) by enhancing anti-tumor immunity. This strategy aims to overcome treatment resistance and improve long-term survival for MM patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute cognitive effects of interruptions to prolonged sitting with brief standing or physical activity breaks: a systematic review and three-level meta-analysis.

The international journal of behavioral nutrition and physical activity·2026
Same author

Environmental and social influences on nighttime sports participation: A dual-theory perspective from social ecology theory and expectation confirmation theory.

Acta psychologica·2026
Same author

Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma.

Blood·2026
Same author

NHE6-driven endosome-autophagy axis confers proteasome inhibitor resistance in multiple myeloma.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2026
Same author

Effect of breaking up prolonged sitting with physical activity on executive function: a three-level meta-analysis.

The international journal of behavioral nutrition and physical activity·2026
Same author

Lipophilic Grape Seed Proanthocyanidin Attenuates High-Fat Diet-Induced Hyperlipidemia by Modulating Gut Microbiota and Metabolic Profiles.

Journal of agricultural and food chemistry·2026

Area of Science:

  • Immunology
  • Oncology
  • Cell Therapy

Background:

  • Multiple myeloma (MM) remains largely incurable with current therapies, frequently relapsing after initial remission.
  • Chemotherapy and transplantation achieve remission in about 50% of newly diagnosed MM patients but do not prevent relapse.
  • Novel, non-cross-resistant therapies are needed for long-term disease-free survival in MM.

Purpose of the Study:

  • To review the potential of dendritic cell (DC)-based immunotherapy for multiple myeloma (MM).
  • To discuss myeloma antigens, DC antigen presentation capabilities, and T-cell responses.
  • To examine the clinical experience of DC vaccination in MM patients.

Main Methods:

  • Review of scientific literature on DC immunotherapy, myeloma antigens, and immune responses.

Related Experiment Videos

  • Analysis of preclinical data from animal tumor models.
  • Evaluation of clinical trial data for DC vaccination in human malignancies, including MM.

    • Main Results:

    • Dendritic cells (DCs) are potent antigen-presenting cells and natural adjuvants for immunotherapy.
    • Tumor antigen-pulsed DC vaccination has shown efficacy in preclinical models and human cancers.
    • Clinical trials are exploring DC-based strategies for various malignancies, including MM.

    Conclusions:

    • DC-based immunotherapy is a promising strategy to induce or enhance tumor-specific immunity against MM.
    • Understanding myeloma antigens and DC function is crucial for effective DC vaccination.
    • Further clinical investigation of DC vaccination is warranted to improve outcomes for MM patients.